, Singapore
823 views
Photo by Julia Koblitz via Unsplash

65LAB backs NUS biotech venture with $2.13m funding

The capital will help advance a treatment candidate for a chronic lung disease.

Singapore-based venture creation platform 65LAB has committed $2.13m (US$1.66m) to a National University of Singapore (NUS) research project developing a biologic therapy for chronic obstructive pulmonary disease (COPD).

The funding was awarded to associate professor Ruowen Ge from NUS' Department of Biological Sciences and co-principal investigator professor Fred Wong, director of the Drug Discovery and Optimisation Platform and professor in the Department of Pharmacology.

The funding will support pre-clinical development of a potential first-in-class airway-delivered biologic for COPD and other immune cell-driven lung diseases, aimed at advancing the programme towards potential company creation, according to 65LAB.

The NUS team said it has identified an anti-inflammatory protein that, in preclinical studies, reduced lung inflammation, restored lung function, and suppressed COPD.

The candidate is being developed for both T2 and non-T2 COPD.

Ge said the funding will help advance the biologic candidate through pre-clinical development and support the creation of a new company focused on COPD therapies.

The award was made through 65LAB, a Singapore-based venture creation platform established by ClavystBio, Leaps by Bayer, Lightstone Ventures, Polaris Partners, the Polaris Innovation Fund, and life sciences company Evotec.

65LAB said the project was selected through a competitive evaluation process and received support from its investors and partners.

The COPD programme is the third project funded by 65LAB, which was established to support the translation of scientific research into new biotechnology companies in Singapore.

The funding comes as Singapore continues to expand its biotechnology commercialisation ecosystem.

A*STAR and the National University of Singapore launched a joint synthetic biology laboratory on 11 June to help accelerate the commercialisation of research in areas including nutrition, consumer care, and healthcare. 

Join Singapore Business Review community

Follow the link for more news on

Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Top News

Singapore, Sweden deepen clean-energy cooperation
The partnership will focus on hydrogen, ammonia, regional power links and high-voltage transmission technologies.

Exclusives

Singapore opens door to foreign stablecoins under tighter rules
Banks may need separate companies to issue stablecoins under the proposed framework.
Singapore's most notable architecture professionals under 40 of 2026
The honourees span five firms, with women in the majority and a combined portfolio that includes a $960m hospital campus.